Publications

January 2023 (Revised August 2023)
Case

Veeva Systems and the Transformation to a Public Benefit Corporation

By: Ranjay Gulati and Allison M. Ciechanover

Peter Gassner, the co-founder and CEO of Veeva Systems, steered the company through rapid scaling from its launch in 2007 to 2022. Year after year, the company had exceeded expectations, with its market capitalization reaching $50 billion at its peak. By 2022, the... View Details

Keywords: Transformation; Corporate Governance; Corporate Social Responsibility and Impact; Mission and Purpose; Organizational Culture; Information Technology Industry; Technology Industry; United States; California

05 Sep 2023
Book

Failing Well: How Your ‘Intelligent Failure’ Unlocks Your Full Potential

acid deficiency. When the drug was reformulated with folic acid, it passed its efficacy trials, eventually becoming a multibillion-dollar pharmaceutical that helped thousands of lung cancer patients. How to fail intelligently Edmondson,... View Details

Keywords: by Michael Blanding

August 2011 (Revised October 2011)
Case

PureTech Ventures in 2011

By: Andrei Hagiu, Cesar Castro and Sarah Murphy

In early May 2011, Daphne Zohar, founder and managing partner of PureTech Ventures, a life science venture creation company in Boston, MA, was reviewing a term sheet she had just received from a venture capital (VC) firm for one of PureTech's portfolio companies. The... View Details

Keywords: Business Ventures; Business Startups; Venture Capital; Investment; Innovation and Invention; Negotiation; Partners and Partnerships; Science-Based Business; Opportunities; Boston

11 Sep 2012
Working Paper Summaries

Spatial Organization of Firms: Internal and External Agglomeration Economies and Location Choices Through the Value Chain

Keywords: by Juan Alcácer & Mercedes Delgado

June–July 2019
Article

A Methodology for Operationalizing Enterprise IT Architecture and Evaluating Its Modifiability

By: Robert Lagerström, Alan MacCormack, David Dreyfus and Carliss Y. Baldwin

Recent contributions to information systems theory suggest that the primary role of a firm’s information technology (IT) architecture is to facilitate, and therefore ensure the continued alignment of a firm’s IT investments with a constantly changing business... View Details

Keywords: Enterprise Architecture; Modularity; Information Systems; Modifiability; Design Structure Matrix

Read Now

May 2023 (Revised June 2023)
Supplement

Novartis (C): Reimagining Medicine

By: Ramon Casadesus-Masanell, Claudio Feser, Karolin Frankenberger and David Redaschi

This case unfolds around the first-ever approved personalized cancer treatment, how Novartis wrapped it into a new business model design, and how Novartis scaled it. Novartis — one of the largest pharmaceutical companies in the world — is, among other ventures,... View Details

Keywords: Health Testing and Trials; Health Care and Treatment; Business Model; Problems and Challenges; Pharmaceutical Industry; Switzerland

March 2012
Article

Managing Political Risk in Global Business: Beiersdorf 1914-1990

By: Geoffrey Jones and Christina Lubinski

This article is concerned with business strategies of political risk management during the twentieth century. It focuses especially on Beiersdorf, a pharmaceutical and skin care company in Germany. During World War I, the expropriation of its brands and trademarks... View Details

Keywords: Business Strategy; Government and Politics; Risk Management; Brands and Branding; Problems and Challenges; Communication Technology; Cost; Trademarks; Strategy; Pharmaceutical Industry; Germany

Find at Harvard

Read Now

October 1996 (Revised December 1997)
Case

American Cyanamid (A): Boardroom Response to a Hostile Takeover Offer

American Home Products' (AHP) $9 billion hostile takeover of American Cyanamid (Cyanamid) was the largest mergers and-acquistions transaction in 1994, and made AHP the fourth largest pharmaceutical firm in the United States. At the time of AHP's offer, Cyanamid had... View Details

Keywords: Governing and Advisory Boards; Mergers and Acquisitions; Corporate Governance; Pharmaceutical Industry; United States

September 2007
Article

Investigative Negotiation

By: Deepak Malhotra and Max H. Bazerman

This article includes a one-page preview that quickly summarizes the key ideas and provides an overview of how the concepts work in practice along with suggestions for further reading. Negotiators often fail to achieve results because they channel too much effort into... View Details

Keywords: Knowledge Acquisition; Knowledge Use and Leverage; Negotiation Process; Negotiation Tactics; Motivation and Incentives; Perspective; Pharmaceutical Industry

Find at Harvard

11 Sep 2007
First Look

First Look: September 11, 2007

Limited was facing significant pricing pressure in their cash cow business, that primarily consisted of manufacturing Active Pharmaceutical Ingredients (APIs). To combat this commoditization, Biocon's leadership had chosen an... View Details

Keywords: Martha Lagace

March 2011 (Revised February 2012)
Case

Innovation and Growth at Actelion Ltd.

By: Gary P. Pisano, Daniela Beyersdorfer and Ruth Dittrich

In late 2010, Jean-Paul Clozel, CEO of the Swiss biotech pharmaceuticals firm Actelion, looks back on a successful decade. The small venture that he had started with a few of his scientist colleagues in the late 1990s to discover novel medicine in a research-driven... View Details

Keywords: Business Model; Talent and Talent Management; Innovation and Management; Leadership; Growth and Development Strategy; Product Development; Organizational Culture; Research and Development; Pharmaceutical Industry; Pharmaceutical Industry; Switzerland

January 2001 (Revised July 2003)
Case

Pharmacyclics: Financing Research & Development

By: Malcolm P. Baker, Richard S. Ruback and Aldo Sesia

Pharmacyclics (NASDAQ: PCYC), a pharmaceutical company that manufactures products that will improve existing therapeutic treatments for cancer, arteriosclerosis, and retinal disease, was considering a $60 million private placement in February 2000. The company had more... View Details

Keywords: Valuation; Cash Flow; Financing and Loans; Business Startups; Financial Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry

October 2019
Supplement

Impax Laboratories: Executing Accretive Transactions (A)

By: Benjamin C. Esty and Daniel Fisher

Impax Laboratories was a technology-based pharmaceutical company that used a “dual platform” strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the... View Details

Keywords: Financial Reporting; Financial Statements; Mergers and Acquisitions; Capital Structure; Financial Strategy; Competition; Competitive Advantage; Corporate Strategy; Pharmaceutical Industry; United States

October 2019
Case

Impax Laboratories: Executing Accretive Acquisitions (A)

By: Benjamin C. Esty and Daniel Fisher

Impax Laboratories was a technology-based pharmaceutical company that used a “dual platform” strategy to sell both generic and branded treatments. While Impax had grown organically for most of its history, it was beginning to use major acquisitions for growth. In the... View Details

Keywords: Financial Reporting; Financial Statements; Mergers and Acquisitions; Capital Structure; Competition; Competitive Advantage; Corporate Strategy; Pharmaceutical Industry; United States

January 2014 (Revised December 2014)
Case

GenapSys: Business Models for the Genome

By: Richard G. Hamermesh, Joseph B. Fuller and Matthew Preble

GenapSys, a California-based startup, was soon to release a new DNA sequencer that the company's founder, Hesaam Esfandyarpour, believed was truly revolutionary. The sequencer would be substantially less expensive—potentially costing just a few thousand dollars—and... View Details

Keywords: DNA Sequencing; Life Sciences; Business Model; Innovation ＆ Entrepreneurship; Health Care and Treatment; Genetics; Business Strategy; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; Pharmaceutical Industry; United States

May 2021
Case

André Hoffmann: Beyond Philanthropy

By: Lauren Cohen, Hao Gao, Jiawei Ye and Spencer C.N. Hagist

André Hoffmann is a leader of one of the world's largest pharmaceutical companies. His exceptional tenure in philanthropy over the past several decades, including being president of the WWF and the vice-president of the MAVA Foundation, has allowed him access to a far... View Details

Keywords: Strategy; Philanthropy and Charitable Giving; Restructuring; Social Entrepreneurship; Values and Beliefs; Corporate Social Responsibility and Impact; Environmental Sustainability; Cash Flow; Macroeconomics; Ethics; Business and Stakeholder Relations; Switzerland; United States; Japan

June 2024 (Revised December 2024)
Case

Lana Ghanem: Pushing the Boundaries of Health Care Through Venture Capital

By: Joshua D. Margolis and Ahmed Dahawy

Lana Ghanem, managing director of Hikma Ventures, the corporate venture arm of larger pharmaceutical group Hikma, is considering how to grow the venture arm as well as progress her own career. Over the past few years Hikma's executive team had been pressuring the... View Details

Keywords: Business Divisions; Corporate Entrepreneurship; Investment; Corporate Governance; Health Care and Treatment; Leadership Development; Business or Company Management; Growth and Development Strategy; Business Strategy; Venture Capital; Personal Development and Career; Pharmaceutical Industry; Pharmaceutical Industry; Jordan